Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • July 2009 (Revised May 2010)
  • Case
  • HBS Case Collection

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred
  • Format:Print
  • | Pages:19
ShareBar

Abstract

This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to examine these decisions, the case provides excerpts from four Chairman's letters to shareholders from Pfizer's annual reports, followed by a description of the circumstances behind each letter. In the 2000 annual report, then-CEO Bill Steere discusses Pfizer's rise to industry prominence with the acquisition of Warner-Lambert. In the 2003 report, new CEO Hank McKinnell discusses Pfizer's performance goals and its acquisition of Pharmacia, which gave it control of the anti-arthritis drug Celebrex. In the 2005 report, McKinnell discusses his decision to keep Celebrex on the market despite health risks. In the 2006 report, new CEO Jeff Kindler barely mentions McKinnell's (controversial) early retirement and describes efforts to reform the company. The case closes in February 2009, just after Pfizer announces plans to acquire competitor Wyeth. Since 2000, Pfizer's tremendous growth in assets through acquisitions has not translated into significant growth in net income or share price. In closing, students are asked what Kindler should write in the letter to shareholders to open Pfizer's 2008 annual report.

Keywords

Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States

Citation

Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
  • Educators
  • Purchase

About The Author

Robert Simons

Accounting and Management
→More Publications

More from the Authors

    • March 2022
    • Faculty Research

    John F. Kennedy: Changing the World

    By: Robert Simons and Max Saffer
    • February 2022
    • Faculty Research

    P.T. Barnum: Changing the World

    By: Robert Simons and Shirley Sun
    • February 2022
    • Faculty Research

    Henkel: Building a Winning Culture (C)

    By: Robert L. Simons and Carolyn Deller
More from the Authors
  • John F. Kennedy: Changing the World By: Robert Simons and Max Saffer
  • P.T. Barnum: Changing the World By: Robert Simons and Shirley Sun
  • Henkel: Building a Winning Culture (C) By: Robert L. Simons and Carolyn Deller
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College